Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARTEMIDE-Lung03: Rilvegostomig vs Pembrolizumab in 1L Non-squamous NSCLC
NCT06627647Phase 3Recruiting
- Sponsor
- AstraZeneca
- Start
- Nov 2024
- Primary completion
- Nov 2030
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 25
01
Overview
Phase 3, randomised, double-blind trial of rilvegostomig in Nonsquamous Non-Small Cell Lung Cancer (nsNSCLC) (2 arms), sponsored by AstraZeneca. Primary endpoints: Overall survival and Progression-free survival. Started Nov 2024; status: recruiting.
02
Drugs
rilvegostomig
03
Conditions
Nonsquamous Non-Small Cell Lung Cancer (nsNSCLC)
Beyond the preview
Go deeper on NCT06627647.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06627647.